{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:15:56Z","timestamp":1790511356417,"version":"4.1.0"},"reference-count":152,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus. COVID-19 vaccines have proven to be successful in protecting the vaccinated from infection, reducing the severity of disease, and deterring the transmission of infection. However, COVID-19 vaccination faces many challenges, such as the decline in vaccine-induced immunity over time, and the decrease in potency against some SARS-CoV-2 variants including the recently emerged Omicron variant, resulting in breakthrough infections. The challenges that COVID-19 vaccination is facing highlight the importance of the discovery of antivirals to serve as another means to tackle the pandemic. To date, neutralizing antibodies that block viral entry by targeting the viral spike protein make up the largest class of antivirals that has received US FDA emergency use authorization (EUA) for COVID-19 treatment. In addition to the spike protein, other key targets for the discovery of direct-acting antivirals include viral enzymes that are essential for SARS-CoV-2 replication, such as RNA-dependent RNA polymerase and proteases, as judged by US FDA approval for remdesivir, and EUA for Paxlovid (nirmatrelvir + ritonavir) for treating COVID-19 infections. This review presents an overview of the current status and future direction of antiviral drug discovery for treating SARS-CoV-2 infections, covering important antiviral targets such as the viral spike protein, non-structural protein (nsp) 3 papain-like protease, nsp5 main protease, and the nsp12\/nsp7\/nsp8 RNA-dependent RNA polymerase complex.<\/jats:p>","DOI":"10.3390\/v14050961","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T10:49:30Z","timestamp":1651661370000},"page":"961","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Antiviral Drug Discovery for the Treatment of COVID-19 Infections"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8333-2446","authenticated-orcid":false,"given":"Teresa I.","family":"Ng","sequence":"first","affiliation":[{"name":"Virology Drug Discovery, AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Correia","sequence":"additional","affiliation":[{"name":"Department of Cell and Protein Sciences, Drug Discovery Science and Technology, AbbVie Inc., Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Seagal","sequence":"additional","affiliation":[{"name":"Department of Biologics Discovery, Drug Discovery Science and Technology, AbbVie Inc., Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"DeGoey","sequence":"additional","affiliation":[{"name":"Department of Centralized Medicinal Chemistry, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Schrimpf","sequence":"additional","affiliation":[{"name":"Department of Centralized Medicinal Chemistry, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hardee","sequence":"additional","affiliation":[{"name":"Department of Centralized Medicinal Chemistry, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Noey","sequence":"additional","affiliation":[{"name":"Department of Structural Biology, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren M.","family":"Kati","sequence":"additional","affiliation":[{"name":"Virology Drug Discovery, AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"(2022, March 21). COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University. Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa030685","article-title":"A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong","volume":"348","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning Immunity after the BNT162b2 Vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost","volume":"1","author":"Ai","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lusvarghi, S., Pollett, S.D., Neerukonda, S.N., Wang, W., Wang, R., Vassell, R., Epsi, N.J., Fries, A.C., Agan, B.K., and Lindholm, D.A. (2021). SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv.","DOI":"10.1101\/2021.12.22.473880"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109721","DOI":"10.1016\/j.cellsig.2020.109721","article-title":"Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of COVID-19","volume":"74","author":"Poduri","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"671263","DOI":"10.3389\/fmolb.2021.671263","article-title":"Current Strategies of Antiviral Drug Discovery for COVID-19","volume":"8","author":"Mei","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: Drug Targets and Potential Treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165878","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Biochim. et Biophys. Acta (BBA)\u2013Mol. Basis Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107930","DOI":"10.1016\/j.pharmthera.2021.107930","article-title":"Drug repurposing for COVID-19: Approaches, challenges and promising candidates","volume":"228","author":"Ng","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17460441.2021.1863943","article-title":"Can drug repurposing strategies be the solution to the COVID-19 crisis?","volume":"16","author":"Bellera","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"ref_24","unstructured":"(2022, March 21). Prescribing Information for Veklurytm (Remdesivir). Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/COVID-19\/veklury\/veklury_pi.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-4-14","article-title":"The journey of remdesivir: From Ebola to COVID-19","volume":"9","author":"Pardo","year":"2020","journal-title":"Drugs Context"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing A Direct Acting, Orally Available Antiviral Agent in a Pandemic: The Evolution of Molnupiravir as a Potential Treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02428-20","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","unstructured":"(2022, March 21). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir, Available online: https:\/\/www.fda.gov\/media\/155054\/download."},{"key":"ref_29","unstructured":"(2022, March 21). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. Available online: https:\/\/www.covid19oralrx-patient.com\/files\/Final-Emergency-Use-Full-Prescribing-Info-HCP-Fact-Sheet-COVID-19-Oral-Antiviral.pdf."},{"key":"ref_30","unstructured":"NIH COVID-19 Treatment Guidelines (2022, March 21). Ritonavir-Boosted Nirmatrelvir (Paxlovid), Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antiviral-therapy\/ritonavir-boosted-nirmatrelvir--paxlovid-\/."},{"key":"ref_31","unstructured":"FDA (2022, March 21). Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant. Press Announcements, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv. Virus Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Finkelstein, M., Mermelstein, A., Miller, E., Seth, P., Stancofski, E.-S., and Fera, D. (2021). Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses, 13.","DOI":"10.3390\/v13010134"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/acscentsci.0c01056","article-title":"Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein","volume":"6","author":"Casalino","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.abf4830","article-title":"Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody","volume":"371","author":"Rappazzo","year":"2021","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2021","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","article-title":"The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets","volume":"6","author":"Peacock","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e20200537","DOI":"10.1084\/jem.20200537","article-title":"Forty years with coronaviruses","volume":"217","author":"Weiss","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1016\/j.jmb.2017.10.017","article-title":"The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner","volume":"429","author":"Lai","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","article-title":"A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Barnes, C.O., Jette, C.A., Abernathy, M.E., Dam, K.M.A., Esswein, S.R., Gristick, H.B., Malyutin, A.G., Sharaf, N.G., Huey-Tubman, K.E., and Lee, Y.E. (2020). Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies. bioRxiv.","DOI":"10.1101\/2020.08.30.273920"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eabl6251","DOI":"10.1126\/science.abl6251","article-title":"Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain","volume":"375","author":"Nabel","year":"2022","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"110210","DOI":"10.1016\/j.celrep.2021.110210","article-title":"Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern","volume":"38","author":"Li","year":"2022","journal-title":"Cell Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00902-20","DOI":"10.1128\/JVI.00902-20","article-title":"Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes","volume":"94","author":"Guo","year":"2020","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-virology-101416-041718","article-title":"Mechanisms and Concepts in RNA Virus Population Dynamics and Evolution","volume":"5","author":"Dolan","year":"2018","journal-title":"Annu. Rev. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"key":"ref_64","unstructured":"Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., and Msomi, N. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv, 2020."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sheward, D.J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G.M., Albert, J., and Murrell, B. (2022). Structural basis of Omicron neutralization by affinity-matured public antibodies. bioRxiv.","DOI":"10.1101\/2022.01.03.474825"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Westendorf, K., \u017dentelis, S., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., and Sauder, J.M. (2022). LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv.","DOI":"10.1016\/j.celrep.2022.110812"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1021\/acs.jcim.1c00560","article-title":"Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation","volume":"61","author":"Jawad","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"109929","DOI":"10.1016\/j.celrep.2021.109929","article-title":"Stabilized coronavirus spike stem elicits a broadly protective antibody","volume":"37","author":"Hsieh","year":"2021","journal-title":"Cell Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"eabi9215","DOI":"10.1126\/scitranslmed.abi9215","article-title":"A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection","volume":"14","author":"Zhou","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41594-021-00596-4","article-title":"Structural basis for broad coronavirus neutralization","volume":"28","author":"Sauer","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1107\/S2052252521010113","article-title":"Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography","volume":"8","author":"Kneller","year":"2021","journal-title":"IUCrJ"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gr.849004","article-title":"WebLogo: A Sequence Logo Generator","volume":"14","author":"Crooks","year":"2004","journal-title":"Genome Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e2024302118","DOI":"10.1073\/pnas.2024302118","article-title":"Drugs repurposed for COVID-19 by virtual screening of 6218 drugs and cell-based assay","volume":"118","author":"Jang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","article-title":"Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease","volume":"56","author":"Jacobs","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","article-title":"Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations","volume":"7","author":"Zhang","year":"2021","journal-title":"ACS Central Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/d41586-021-01571-1","article-title":"A white-knuckle ride of open COVID drug discovery","volume":"594","author":"Calmiano","year":"2021","journal-title":"Nature"},{"key":"ref_80","unstructured":"Achdout, H., Aimon, A., Bar-David, E., Barr, H., Ben-Shmuel, A., Bennett, J., Boby, M.L., Borden, B., Bowman, G.R., and Brun, J. (2021). Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics. bioRxiv."},{"key":"ref_81","unstructured":"Shionogi (2022, March 21). Shionogi R&D Day 2021. Available online: https:\/\/www.shionogi.com\/content\/dam\/shionogi\/global\/investors\/ir-library\/presentation\/2021\/e_20210929_4.pdf."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Sasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura, K., Toba, S., Kusakabe, S., and Maruyama, Y. (2022). Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19. bioRxiv.","DOI":"10.1101\/2022.02.14.480338"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_84","unstructured":"Anivive (2022, March 21). Anivive Repurposes Veterinary Drug GC376 for COVID-19 and Submits Pre-IND to FDA. Available online: https:\/\/www.prnewswire.com\/news-releases\/anivive-repurposes-veterinary-drug-gc376-for-covid-19-and-submits-pre-ind-to-fda-301065619.html."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_88","unstructured":"Pfizer (2022, March 21). Pfizer\u2019s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2\/3 EPIC-HR Study. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate."},{"key":"ref_89","unstructured":"Enanta (2022, March 21). Enanta Pharmaceuticals Presents New Data for Edp-235, Its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at The ISIRV\u2013Who Virtual Conference 2021. Available online: https:\/\/www.enanta.com\/investors\/news-releases\/press-release\/2021\/Enanta-Pharmaceuticals-Presents-New-Data-for-EDP-235-its-Lead-Oral-Protease-Inhibitor-Designed-for-the-Treatment-of-COVID-19-at-the-ISIRVWHO-Virtual-Conference-2021\/default.aspx."},{"key":"ref_90","unstructured":"Cocrystal Pharam (2022, March 21). Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for Its COVID-19 Oral Drug Program. Available online: https:\/\/www.cocrystalpharma.com\/news\/press-releases\/detail\/139\/cocrystal-pharma-selects-two-lead-antiviral-drug-candidates."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbrc.2021.03.096","article-title":"ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model","volume":"555","author":"Vandyck","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","article-title":"The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing","volume":"96","author":"Snijder","year":"2016","journal-title":"Adv. Virus Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coviro.2021.03.010","article-title":"Structure and function of SARS-CoV-2 polymerase","volume":"48","author":"Hillen","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Geraghty, R., Aliota, M., and Bonnac, L. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 13.","DOI":"10.3390\/v13040667"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Sofia, M.J. (2014). Nucleosides and Nucleotides for the Treatment of Viral Diseases. Annual Reports in Medicinal Chemistry, Academic Press.","DOI":"10.1016\/B978-0-12-800167-7.00015-8"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1074\/jbc.AC120.015720","article-title":"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action","volume":"295","author":"Tchesnokov","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e02479-20","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"16577","DOI":"10.1038\/s41598-020-73641-9","article-title":"Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir","volume":"10","author":"Jockusch","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"20117","DOI":"10.1039\/D1CP03049C","article-title":"Incorporation efficiency and inhibition mechanism of 2\u2032-substituted nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase","volume":"23","author":"Yuan","year":"2021","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2014preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium (2021). Repurposed Antiviral Drugs for COVID-19\u2014Interim WHO Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"106272","DOI":"10.1016\/j.cct.2021.106272","article-title":"Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Bizanti","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2021.09.009","article-title":"Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses","volume":"564","author":"Wang","year":"2021","journal-title":"Virology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N 4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_121","unstructured":"BioCryst (2022, March 21). BioCryst Provides Update on Galidesivir Program. Available online: https:\/\/ir.biocryst.com\/news-releases\/news-release-details\/biocryst-provides-update-galidesivir-program."},{"key":"ref_122","unstructured":"Atea (2022, March 21). Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting. Available online: https:\/\/ir.ateapharma.com\/news-releases\/news-release-details\/atea-pharmaceuticals-provides-update-and-topline-results-phase-2."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12985-020-01412-z","article-title":"Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and meta-analysis","volume":"17","author":"Shrestha","year":"2020","journal-title":"Virol. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1073\/pnas.1720975115","article-title":"Future of nonnucleoside reverse transcriptase inhibitors","volume":"115","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In Vitro Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.1c00118","article-title":"DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges","volume":"4","author":"Donckele","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-020-2117-z","article-title":"An open-source drug discovery platform enables ultra-large virtual screens","volume":"580","author":"Gorgulla","year":"2020","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102021","DOI":"10.1016\/j.isci.2020.102021","article-title":"A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening","volume":"24","author":"Gorgulla","year":"2021","journal-title":"iScience"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.11.001","article-title":"Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein","volume":"149","author":"Lei","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Mesecar","year":"2015","journal-title":"Antiviral. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/embor.2011.17","article-title":"Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21","volume":"12","author":"Ye","year":"2011","journal-title":"EMBO Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/v2081803","article-title":"Coronavirus Genomics and Bioinformatics Analysis","volume":"2","author":"Woo","year":"2010","journal-title":"Viruses"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_136","first-page":"210","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"575","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","article-title":"The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme","volume":"79","author":"Lindner","year":"2005","journal-title":"J. Virol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2013.11.040","article-title":"MERS-CoV papain-like protease has deISGylating and deubiquitinating activities","volume":"450-451","author":"Mielech","year":"2014","journal-title":"Virology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"32208","DOI":"10.1074\/jbc.M704870200","article-title":"Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus","volume":"282","author":"Devaraj","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.molcel.2016.04.016","article-title":"Recognition of Lys48-Linked Di-ubiquitin and Deubiquitinating Activities of the SARS Coronavirus Papain-like Protease","volume":"62","author":"Ekkebus","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm900611t","article-title":"Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome\u2014Coronavirus Papain-Like Protease","volume":"52","author":"Ghosh","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein\u2212Ligand X-ray Structure and Biological Evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity","volume":"65","author":"Shen","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.chembiol.2021.04.020","article-title":"Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2","volume":"28","author":"Shan","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Central Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti\u2013COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1021\/acs.jmedchem.1c02022","article-title":"Design and Evaluation of a Novel Peptide\u2013Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-like Protease","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41598-021-83229-6","article-title":"Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2","volume":"11","author":"Tomczak","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Cathcart, A.L., Havenar-Daughton, C., Lempp, F.A., Ma, D., Schmid, M.A., Agostini, M.L., Guarino, B., Rosen, L.E., Tucker, H., and Dillen, J. (2021). The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv.","DOI":"10.1101\/2021.03.09.434607"},{"key":"ref_152","unstructured":"NIH (2022, March 21). Biden Administration to Invest $3 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy, Available online: https:\/\/www.niaid.nih.gov\/news-events\/biden-administration-invest-3-billion-american-rescue-plan-part-covid-19-antiviral."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/961\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:06:05Z","timestamp":1760137565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":152,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["v14050961"],"URL":"https:\/\/doi.org\/10.3390\/v14050961","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]}}}